Stocktoria
Actinium Pharmaceuticals, Inc. ATNM
Actinium Pharmaceuticals, Inc. (ATNM) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $90,000 at a -37652.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ATNM | Actinium Pharmaceuticals, Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| INO | INOVIO PHARMACEUTICALS, INC. | — | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| BFRG | BullFrog AI Holdings, Inc. | 1/9 | — | — | — |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
FAQ
Is ATNM financially healthy?
Actinium Pharmaceuticals, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does ATNM pay a dividend?
No, Actinium Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is ATNM?
In FY2025, Actinium Pharmaceuticals, Inc. had a net margin of -37652.2% and a return on equity of -432.6%.
What is the analyst price target for ATNM?
The average Wall-Street price target for Actinium Pharmaceuticals, Inc. is $5.00, about 508.9% above the recent price, from 4 analysts.
Is ATNM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Actinium Pharmaceuticals, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.